← Jürgen C. Becker

Papers by Jürgen C. Becker

Page 2 · newest first

51. The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repressionJournal of Cancer Research and Clinical Oncology · 2023
52. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGJournal for ImmunoTherapy of Cancer · 2023
53. COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center studyFrontiers in Immunology · 2023
54. An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary ResultsDermato · 2023
55. S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2023
56. Identification of Epigenetically Regulated Genes Distinguishing Intracranial from Extracranial Melanoma MetastasesJournal of Investigative Dermatology · 2023
57. Phenotypic plasticity of malignant T cells in blood and skin of a Sézary syndrome patient revealed by single cell transcriptomicsFrontiers in Oncology · 2023
58. The Antineoplastic Effect of Dimethyl Fumarate on Virus-Negative Merkel Cell Carcinoma Cell Lines: Preliminary ResultsCancers · 2023
59. German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – Long version of the update 2023EJC Skin Cancer · 2023
60. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREGJournal for ImmunoTherapy of Cancer · 2022
61. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphomaBlood · 2022
62. Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCLCancers · 2022
63. Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma PatientsSHILAP Revista de lepidopterología · 2022
64. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022European Journal of Cancer · 2022
65. Persister state-directed transitioning and vulnerability in melanomaNature Communications · 2022
66. Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitorsJournal of Cancer Research and Clinical Oncology · 2022
67. Characterization of a novel microfluidic platform for the isolation of rare single cells to enable CTC analysis from head and neck squamous cell carcinoma patientsEngineering in Life Sciences · 2022
68. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesisNeuro-Oncology · 2022
69. Knockout of Factor-Inhibiting HIF (Hif1an) in Colon Epithelium Attenuates Chronic Colitis but Does Not Reduce Colorectal Cancer in MiceThe Journal of Immunology · 2022
70. Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinomaJournal of Cancer Research and Clinical Oncology · 2022
71. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaJournal for ImmunoTherapy of Cancer · 2022
72. Bullous pemphigoid after SARS‐CoV‐2 vaccination: spike‐protein‐directed immunofluorescence confocal microscopy and T‐cell‐receptor studiesBritish Journal of Dermatology · 2021
73. Waiving Subsequent Complete Lymph Node Dissection in Melanoma Patients with Positive Sentinel Lymph Node Does Not Result in Worse Outcome on 20-Year AnalysisSHILAP Revista de lepidopterología · 2021
74. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter AnalysisFrontiers in Oncology · 2021
75. DNA-methylation patterns imply a common cellular origin of virus- and UV-associated Merkel cell carcinomaOncogene · 2021
76. Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B CellsFrontiers in Immunology · 2021
77. Comparison of mutation profiles in primary melanomas and corresponding nodal naevi using next‐generation sequencingClinical and Experimental Dermatology · 2021
78. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaFrontiers in Oncology · 2021
79. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*British Journal of Dermatology · 2021
80. Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progressionNature Communications · 2021
81. Expression of Mismatch Repair Proteins in Merkel Cell CarcinomaCancers · 2021
82. New Insights into the Biological and Clinical Aspects of Merkel Cell CarcinomaTyöväentutkimus Vuosikirja · 2021
83. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG studyCancer Immunology Immunotherapy · 2021
84. Expression of Potential Targets for Cell-Based Therapies on Melanoma CellsLife · 2021
85. Expression of Hedgehog signalling molecules in microcystic adnexal carcinomaClinical and Experimental Dermatology · 2021
86. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancerCancer Treatment Reviews · 2021
87. Mutational Landscape of Virus- and UV-Associated Merkel Cell Carcinoma Cell Lines Is Comparable to Tumor TissueCancers · 2021
88. Assessment of soft and hard tissue dimensions following different treatment approaches of ligature‐induced peri‐implantitis defectsClinical Oral Implants Research · 2021
89. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinomaCancer Immunology Immunotherapy · 2021
90. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapyNature Communications · 2021
91. Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53Oncogene · 2020
92. BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytesCancer Immunology Immunotherapy · 2020
93. Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 InfectionCancers · 2020
94. Patched 1 expression in Merkel cell carcinomaThe Journal of Dermatology · 2020
95. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsSHILAP Revista de lepidopterología · 2020
96. SARS‐CoV‐2 spike protein is present in both endothelial and eccrine cells of a chilblain‐like skin lesionJournal of the European Academy of Dermatology and Venereology · 2020
97. The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma CellsJournal of Investigative Dermatology · 2020
98. There is still a place for tumour‐targeted therapies in Merkel cell carcinoma in the era of immune checkpoint inhibitorsBritish Journal of Dermatology · 2020
99. High-resolution analysis of Merkel Cell Polyomavirus in Merkel Cell Carcinoma reveals distinct integration patterns and suggests NHEJ and MMBIR as underlying mechanismsPLoS Pathogens · 2020
100. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19Journal for ImmunoTherapy of Cancer · 2020